Boundless Bio, Inc.

For the period ended Mar 31, 2026. Filed May 8, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 8, 2026

BOLD$2.45-0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

(in thousands)

	Three Months EndedMarch 31,
	2026	2025
Cash flows from operating activities
Net loss	$(13,555)	$(15,758)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,371	1,797
Depreciation and amortization	284	317
Accretion of investments, net	(333)	(816)
Non-cash lease expense	829	857
Changes in operating assets and liabilities:
Prepaid expenses and other assets	250	214
Accounts payable and accrued liabilities	(3,071)	(2,083)
Operating lease liabilities	(747)	942
Net cash used in operating activities	(14,972)	(14,530)
Cash flows from investing activities
Purchases of investments	(29,405)	(52,625)
Maturities of investments	44,000	55,744
Purchases of property and equipment	(8)	(59)
Net cash provided by investing activities	14,587	3,060
Cash flows from financing activities
Net cash provided by (used in) financing activities	—	—
Net decrease in cash, cash equivalents, and restricted cash	(385)	(11,470)
Cash, cash equivalents, and restricted cash at beginning of period	18,428	27,147
Cash, cash equivalents, and restricted cash at end of period	$18,043	$15,677
Components of cash, cash equivalents, and restricted cash
Cash and cash equivalents	$17,483	$15,117
Restricted cash	560	560
Cash, cash equivalents, and restricted cash at end of period	$18,043	$15,677

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.